- Governance principles
- General Meeting
- Annual General Meeting 2024
- Board of Directors
- Management Team
- Remuneration
- Risk management
- Insider management
- Managers' transactions
- Flagging notifications
- Auditor
- Articles of Association
- Code of Conduct
- Stock Exchange Releases
- Company releases
- Press releases
- Managers' transactions
- Flagging notifications
- En
- Fi
Welcome to Nightingale Health's investor pages
On our investor pages, you can read about Nightingale Health as an investment, find our latest releases and reports as well as follow Nightingale Health's share price development.
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check for the health industry. Our solution provides risk detection for multiple chronic diseases from a single blood sample.
Nightingale Health Check can be scaled to entire populations at a low cost, and it can replace many of the current risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases.
Contact us
ir@nightingalehealth.com
Half-year report 1 July - 31 December 2024 has been published
Latest releases
Conversion of Nightingale Health Plc’s Series A shares to Series B shares
Trading in Nightingale Health's B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US
Nightingale Health Plc's listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025
The Finnish Financial Supervisory Authority has approved Nightingale Health Plc's Finnish prospectus
Nightingale Health establishes ADR program in the US - trading in Company's B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US
Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki
Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States
Nightingale Health to publish half-year report for July - December 2024 on 6 March 2025
Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region
